TargetGene Biotechnologies Overview
TargetGene Biotechnologies is an innovative and agile biotechnology company in its development stage and poised for expansion. The companys R&D is centered around creating efficient and extremely specific DNA editing solutions in living organisms. Through its patented and patent-pending TGEE (genome editing engine) platform, TargetGene has developed RNA-guided gene targeting. The company aims to implement the TGEE platform for human gene therapy with a focus on inherited diseases and cell-based immunotherapy.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Interview: Move over CRISPR: a new platform, TGEE, could soon replace everybody's favorite gene editing tool. Interview: Yoel Shiboleth, CEO TargetGene - CRISPR Medicine
TargetGene Biotechnologies, a genome editing company, has developed a unique molecular tool for editing DNA with higher specificity than CRISPR/Cas9. The companys system, called TGEE (TargetGene Genome-Editing Engine), uses two RNAs to guide the DNA-cutting enzymes to their target, making it much more specific and unlikely to cut unintended off-target sites in the genome. The system is currently about half as efficient as CRISPR, but the company believes it can improve efficiency to match or surpass CRISPR. TargetGene is targeting three therapeutic areas: cancer, hereditary diseases, and autoimmune diseases. The company is seeking investors to support its technology, and it aims to obtain FDA approval for its first application within a year and a half.
InvestmentExpand
growth-positive
TargetGene develops more precise gene editing
TargetGene Biotechnologies, a company specializing in gene editing, has developed an improved version of the CRISPR method. The companys founders, Dan Weinthal and Dr. Yoel Shiboleth, have experience in genetic engineering and have invented a protein that cuts DNA more precisely than CRISPR. TargetGene aims to replace CRISPR in human trials and believes its product is safer and more precise. The company is currently focused on medical applications of its technology, particularly in cancer treatment. TargetGene has received investments from Makhteshim Agan and Monsanto, and recently signed an agreement with a global drug manufacturer. The company is seeking additional financing to bring its product to market.
InvestmentPartners
Next Phase of High-Tech Crops: Editing Their Genes
growth-positive
Monsanto Inks Gene Editing Tech Licensing Deals With TargetGene, Nomad Bioscience
Monsanto has announced two new licensing agreements for genome editing technologies with TargetGene Biotechnologies and Nomad Bioscience. Under the agreements, Monsanto has obtained exclusive licenses and equity positions in both firms. The agreements allow Monsanto to use TargetGenes genome editing engine (T-Gee) and Nomads technology for research projects and potentially for the development of commercial agricultural products. The partnerships aim to improve the efficiency of genome editing and the ability to deploy edited traits in commercial varieties. The financial terms of the agreements were not disclosed.
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $9.2M |
| Last funding | $6.7M |
| Stage | B |
| Rounds | 2 |
| Investors | 2 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | targetgenebio.com |
| Careers | Careers page |
Locations
Prof. Hillel ve-Khanan Oppenheimer St 10, Rehovot, Israel
Photos & Videos
2 item(s)